Isothermal Nucleic Acid Amplification Patents: Leaders & Trends 2026
- 26.8% concentration at the top. The five leading assignees combined account for 992 of the 3,697 records in scope — a dense core around a long tail of single- and few-filing entrants.
- Filings peaked in 2021 at 397. Volume has since fallen to 124 by 2024, a -69% move over that three-year span; 2025 and later years are still filling in as publications lag filing by roughly 18 months.
- C12Q dominates at 82.6%. Enzyme- and DNA-measurement claims under C12Q cover the large majority of the 3,697 records, while apparatus classes like B01L and C12M remain comparatively thin.
Filing growth compares 2021 (397 records) with 2024 (124) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 3,697 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
Isothermal nucleic acid amplification — including loop-mediated amplification and related methods — replaces thermal cycling with a single reaction temperature, which shifts much of the patent activity toward primer design, enzyme selection, and control of nonspecific amplification rather than thermocycler engineering. This landscape draws on 3,697 records published between 2015 and mid-2026 that combine isothermal amplification methods with claims touching primer design, reaction temperature, nonspecific amplification, amplification speed, enzyme selection, or multiplex capability.
The picture that emerges is a field with a genuinely concentrated core — a handful of academic and diagnostics assignees holding a meaningful share of the record base — sitting alongside a long tail of smaller filers working narrower device and workflow claims. Filing activity rose sharply through the late 2010s, peaked in 2021, and has since pulled back, though the most recent years understate true activity because publication lags filing.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trends and technology composition
The trend and classification charts below are built from the same 3,697-record set referenced throughout this page, so every share and count ties back to that denominator.
Filings rose to a 2021 peak, then pulled back
Annual filings climbed from 182 in 2017 to a peak of 397 in 2021, then declined to 124 by 2024 — a -69% move over that span. Treat 2025 and 2026 as incomplete rather than as evidence of a further slowdown, since publication typically lags filing by around 18 months.
C12Q carries the large majority of records
C12Q (measuring and testing involving enzymes or DNA) appears in 82.6% of the 3,697 records, far ahead of C12N genetic engineering claims at 29.0% and G01N analytical methods at 21.6%. Apparatus-oriented classes — B01L lab devices, C12M bioreactors, C40B combinatorial libraries — are present but comparatively thin, which is where hardware-side claim space still has room.
Shares are the percentage of the 3,697 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Isothermal Nucleic Acid Amplification with Eureka
This page is one run against one query. Ask Eureka your own question about isothermal nucleic acid amplification and every answer comes back with the patent numbers behind it.
Try EurekaThe most-cited records anchoring this field
Point-of-care incubator for isothermal nucleic acid amplification tests (PIINT)
This invention provides a point-of-care (POC) device for isothermal nucleic acid amplification tests (NAAT). The POC device comprises a housing; a heater disposed in the housing; at least one heat sink disposed in the housing in thermal communications with the heater, and configured to speed up heating and hold reaction tubes containing the NAAT being incubated; and a phase change material adapted for regulating temperature of the reactions. The device targets point-of-care detection of Johne's disease in livestock.Filed by the Board of Trustees of the University of Arkansas, published 2025-02-06 — illustrates how recent activity has moved toward field-deployable hardware around established amplification chemistries rather than new core chemistry claims.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20100120098A1 | Transposon end compositions and methods for modifying nucleic acids | 1,005 |
| 2 | US6251639B1 | Methods and compositions for linear isothermal amplification of polynucleotide sequences, using a RNA-DNA com… | 958 |
| 3 | US6379929B1 | Chip-based isothermal amplification devices and methods | 906 |
| 4 | US7282328B2 | Helicase dependent amplification of nucleic acids | 510 |
| 5 | WO2010048605A1 | Transposon end compositions and methods for modifying nucleic acids | 490 |
| 6 | US20130005585A1 | Nucleic acid encoding reactions | 419 |
| 7 | US20040058378A1 | Helicase dependent amplification of nucleic acids | 410 |
| 8 | US20110287435A1 | Transposon end compositions and methods for modifying nucleic acids | 394 |
| 9 | US20200277663A1 | Methods for determining a location of a biological analyte in a biological sample | 378 |
| 10 | WO2020176788A1 | Profiling of biological analytes with spatially barcoded oligonucleotide arrays | 335 |
Citation counts reflect activity inside this searched corpus and favour older, foundational filings rather than currently active claims — read them as a map of influence, not of present-day priority.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for filing strategy
Three patterns stand out once the record set is broken down by assignee, class and geography.
The core is dense, the tail is long
The five leading assignees combined hold 992 of the 3,697 records in scope, a meaningful concentration for a field this broad. Beyond the ranked leaders, activity spreads across a long tail of single- and few-filing entrants working narrower applications.
Volume has pulled back from its peak
Filings peaked at 397 in 2021 and fell to 124 by 2024. That decline is real across complete years, but 2025 and 2026 figures are still filling in given the typical 18-month lag between filing and publication.
Enzyme and DNA-measurement claims dominate
C12Q appears in the large majority of the 3,697 records, well ahead of C12N genetic-engineering claims at 29.0% and G01N analytical methods at 21.6%. Apparatus classes such as B01L and C12M are present in far fewer records.
Filing is US-anchored with strong PCT and EPO activity
The United States receives the largest single share of filings at 1,123 records, followed by Europe at 688 and the WIPO/PCT route at 476. Australia, Canada and Israel each carry a smaller but non-trivial share.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to isothermal nucleic acid amplification, with the prior art for and against each one.
Who is filing, and where activity has cooled
Momentum among the most active assignees has slowed markedly in the latest year, consistent with the broader post-2021 pullback rather than any single company exiting the space.
One assignee sits well ahead of fifth place
The leading assignee holds 247 records against 169 for the fifth-ranked assignee and 66 for tenth — a steep drop-off that marks this as a field with a genuine leader rather than an even spread.
Academic co-assignment is a defining feature
The strongest co-assignee pairing appears 180 times, with two further academic pairings above 140 — pointing to joint research programmes rather than purely corporate filing strategies at the top of this field.
Latest-year activity has dropped sharply across leaders
Several of the most active historical assignees show zero or near-zero filings in the latest year, with year-over-year declines as steep as -100% for some and -86% to -87% for others still filing at low volume.
| Assignee | Recent year | YoY |
|---|---|---|
| Element Biosciences, Inc. | 2 | -86% |
| 10x Genomics, Inc. | 2 | -87% |
| Massachusetts Institute of Technology | 0 | -100% |
| The Broad Institute, Inc. | 0 | -100% |
| ENZO LIFE SCIENCES INC | 0 | — |
| President and Fellows of Harvard College | 0 | -100% |
| Ionian Technologies, LLC | 0 | -100% |
| Mammoth Biosciences, Inc. | 0 | -100% |
Where to take this analysis
The patterns above point to specific next steps depending on whether the goal is freedom-to-operate, portfolio benchmarking, or identifying open claim space.
Run a freedom-to-operate check against the concentrated core
With 26.8% of records held by five assignees, any new filing touching enzyme selection or primer design in this space should be checked against that core before drafting claims.
Explore assignee claims in EurekaTrack the apparatus and hardware white space
B01L and C12M classes remain comparatively thin against the 82.6% C12Q share, suggesting room in device and incubator claims rather than core chemistry.
Map white space in EurekaWatch for the 2025-2026 filing correction
Because publication lags filing by roughly 18 months, the true trajectory of recent activity will only become visible as later filings publish — worth revisiting this landscape on a rolling basis.
Set up monitoring in EurekaCommon questions about this landscape
The ranking of 100 assignees in this dataset shows a clear leader with 247 records, well ahead of the fifth-ranked assignee at 169 and tenth place at 66. Together the top five hold 992 of the 3,697 records in scope, or 26.8%, which is a meaningful concentration for a field this broad. Beyond that core, filing activity spreads thinly across a long tail of academic institutes, diagnostics companies and smaller entrants, so a full competitive picture requires looking well past the leading names.
Filings grew steadily from 182 in 2017 to a peak of 397 in 2021, then declined to 124 by 2024, a -69% move over that three-year span. That decline across complete years is real, but figures for 2025 and 2026 are still incomplete because publication typically lags filing by around 18 months. The honest reading is that the field has cooled from an unusually active 2020-2021 period rather than that it is currently shrinking.
C12Q, covering measuring and testing methods involving enzymes and DNA, appears in 82.6% of the 3,697 records in scope, making it by far the dominant classification. C12N genetic-engineering claims follow at 29.0% and G01N analytical methods at 21.6%. Apparatus-focused classes such as B01L lab devices and C12M bioreactor systems are present in far fewer records, which is where less-claimed hardware space tends to sit.
This 2025 filing from the University of Arkansas claims a point-of-care incubator that combines a heater, a heat sink and a phase-change material to regulate temperature during isothermal amplification reactions, targeting field diagnostics such as Johne's disease detection in livestock. It sits in the apparatus side of the field rather than in core amplification chemistry, and its claims are narrow enough to specific thermal-management hardware that they should not block alternative incubator designs using different temperature-control approaches. Anyone designing a competing POC incubator should still review its specific heat-sink and phase-change-material claims closely before finalising a thermal design.
The apparatus-side classes — B01L lab devices, C12M bioreactor and enzyme apparatus, and C40B combinatorial libraries — each cover well under a fifth of the 3,697 records, in contrast to the 82.6% coverage of core C12Q chemistry claims. That gap suggests more room to file around field-deployable hardware, multiplex primer panel design, and nonspecific-amplification suppression than around the underlying enzymatic chemistry itself, which is already densely claimed by the leading assignees.
Research Isothermal Nucleic Acid Amplification in depth with Eureka
Go past this page: query the whole isothermal nucleic acid amplification corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.